Skip to main content

Table 4 Safety profile for nanoliposomal irinotecan-based therapy [12]

From: Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

Grade 3–4 AEs

Nanoliposomal irinotecan-based therapy (%)

5-FU and OXA-based therapy weighted average (%) [range]

Diarrhea

13

4.2 [0, 14.2]

Vomiting

11

4.1 [0, 13.5]

Fatigue

14

11.7 [0, 14.8]

Neutropenia

27

21.5 [7.4, 32.7]

Anemia

9

4.5 [0, 14]

Hypokalemia

3

NR

Neurotoxicity

NR

5.3 [0, 12]

Thrombocytopenia

NR

4.9 [0, 11.1]

  1. Abbreviations: 5-FU 5-fluorouracil, AE adverse event, NR not recorded, OXA oxaliplatin